1. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. (November 2018) Authors: Kandolf Sekulovic, L.; Guo, J.; Agarwala, S.; Hauschild, A.; McArthur, G.; Cinat, G.; Wainstein, A.; Caglevic, C.; Lorigan, P.; Gogas, H.; Alvarez, M.; Duncombe, R.; Lebbe, C.; Peris, K.; Rutkowski, P.; Stratigos, A.; Forsea, A.-M.; De La Cruz Merino, L.; Kukushkina, M.; Dummer, R. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acquired generalized lipodystrophy under immune checkpoint inhibition. (1st February 2020) Authors: Haddad, N.; Vidal‐Trecan, T.; Baroudjian, B.; Zagdanski, A.‐M.; Arangalage, D.; Battistella, M.; Gautier, J.‐F.; Lebbe, C.; Delyon, J. Journal: British journal of dermatology Issue: Volume 182:Number 2(2020) Page Start: 477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acquired generalized lipodystrophy under immune checkpoint inhibition. (9th August 2019) Authors: Haddad, N.; Vidal‐Trecan, T.; Baroudjian, B.; Zagdanski, A.‐M.; Arangalage, D.; Battistella, M.; Gautier, J.‐F.; Lebbe, C.; Delyon, J. Journal: British journal of dermatology Issue: Volume 182:Number 2(2020) Page Start: 477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. (12th November 2020) Authors: Haddad, N.; Delyon, J.; Trabelsi Messai, S.; Herms, F.; Leccia, M.T.; Lebbe, C.; Whitney, J.; Bhatia, S.; Basset‐Seguin, N. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. (1st March 2021) Authors: Haddad, N.; Delyon, J.; Trabelsi Messai, S.; Herms, F.; Leccia, M.T.; Lebbe, C.; Whitney, J.; Bhatia, S.; Basset‐Seguin, N. Journal: British journal of dermatology Issue: Volume 184:Number 3(2021) Page Start: 564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort. (1st May 2020) Authors: del Regno, L.; Louveau, B.; Battistella, M.; Sadoux, A.; Baroudjian, B.; Delyon, J.; Serror, K.; Allayous, C.; Lebbe, C.; Mourah, S.; Jouenne, F. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort. (2nd December 2019) Authors: del Regno, L.; Louveau, B.; Battistella, M.; Sadoux, A.; Baroudjian, B.; Delyon, J.; Serror, K.; Allayous, C.; Lebbe, C.; Mourah, S.; Jouenne, F. Journal: British journal of dermatology Issue: Volume 182:Number 5(2020) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Comparison of sun protection modalities in parents and children. (February 2015) Authors: Mortier, L.; Lepesant, P.; Saiag, P.; Robert, C.; Sassolas, B.; Grange, F.; Lhomel, C.; Lebbe, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29(2015)Supplement 2 Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. (1st June 2021) Authors: Reynolds, K.A.; Schlessinger, D.I.; Yanes, A.F.; Godinez‐Puig, V.; Chen, B.R.; Kurta, A.O.; Cotseones, J.K.; Chiren, S.G.; Iyengar, S.; Ibrahim, S.A.; Kang, B.Y.; Worley, B.; Behshad, R.; DeHoratius, D.M.; Denes, P.; Drucker, A.M.; Dzubow, L.M.; Etzkorn, J.R.; Harwood, C.A.; Kim, J.Y.S. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. (11th January 2021) Authors: Reynolds, K.A.; Schlessinger, D.I.; Yanes, A.F.; Godinez‐Puig, V.; Chen, B.R.; Kurta, A.O.; Cotseones, J.K.; Chiren, S.G.; Iyengar, S.; Ibrahim, S.A.; Kang, B.Y.; Worley, B.; Behshad, R.; DeHoratius, D.M.; Denes, P.; Drucker, A.M.; Dzubow, L.M.; Etzkorn, J.R.; Harwood, C.A.; Kim, J.Y.S. Journal: British journal of dermatology Issue: Volume 184:Number 6(2021) Page Start: 1113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗